Answers are grounded in this paper and cite their sources.
Retrospective study uncovers accurate prediction of Clostridium difficile infection in ulcerative colitis using serological markers, suggesting useful noninvasive risk stratification.
At present, there are relatively few studies on the risk model for clostridium difficile infection in patients with ulcerative colitis. This study aims to construct a risk model for moderate-to-severe ulcerative colitis patients with clostridium difficile infection based on serological indicators, in order to identify high-risk patients. In this retrospective study, we ultimately included 252 patients with moderate-to-severe ulcerative colitis and evaluated multiple serological parameters related to the risk of infection. Univariate regression and LASSO regression analyses were used to screen the risk factors for concurrent clostridium difficile infection. A nomogram was established based on seven independent risk factors, and the model was evaluated through internal validation and tenfold cross-validation. Among the 252 patients with moderate-to-severe ulcerative colitis, 20.63% (52/252) had concurrent clostridium difficile infection, while 79.37% (200/252) did not. LASSO regression revealed that cholesterol, low-density lipoprotein, uric acid, fibrinogen, lower hemoglobin levels, use of biological agents and the low-density lipoprotein fibrinogen ratio were independent risk factors for concurrent clostridium difficile infection in patients with moderate-to-severe ulcerative colitis. A nomogram was constructed using these seven risk factors, with an area under the curve of 0.789 (95% CI 0.715 to 0.863) and a consistency index (C-index) of 0.789. In tenfold cross-validation, the C-index was 0.789 and the calibration slope was 1. This indicates that the model is relatively accurate in predicting concurrent clostridium difficile infection in patients with moderate-to-severe ulcerative colitis. We constructed a risk model for moderate-to-severe ulcerative colitis complicated by Clostridium difficile infection using serological indicators. This model shows promise as a noninvasive tool to identify high-risk patients in clinical settings; however, external validation is essential to confirm its generalizability.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: